Literature DB >> 7520912

The native v-Raf.hsp90.p50 heterocomplex contains a novel immunophilin of the FK506 binding class.

L F Stancato1, Y H Chow, J K Owens-Grillo, A W Yem, M R Deibel, R Jove, W B Pratt.   

Abstract

We have recently reported that v-Raf forms a native heterocomplex with rat heat shock protein (hsp) 90 and a 50-kDa phosphoprotein (p50) in stably transfected 3Y1 fibroblasts (Stancato, L. F., Chow, Y-H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. (1993) J. Biol. Chem. 268, 21711-21716). Several members of the nuclear receptor family exist in heterocomplexes containing hsp90 and various members of the immunophilin protein family, including hsp56, an immunophilin of the FK506 binding class (Pratt, W. B. (1993) J. Biol. Chem. 268, 21455-21458). In this work, we have asked if Raf is also associated with an immunophilin. We have immunoadsorbed v-Raf from stably transfected rat 3Y1 fibroblasts and show that the immunoadsorbed v-Raf.hsp90.p50 heterocomplex binds the immunosuppressant drug [3H]FK506. The binding is of high affinity (KD 82 nM) and specific in the sense that it is competed by nonradioactive FK506 and rapamycin but not by cyclosporin A. The [3H]FK506 binding activity is eliminated when the heterocomplex proteins are dissociated from v-Raf. Using the 22W mutant of c-Raf in which the NH2-terminal half has been deleted, we show that the catalytic domain of the kinase is sufficient for the immunophilin association. We have shown that hsp90 and p50 do not bind FK506, and the v-Raf heterocomplex does not contain any of the established FK506-binding proteins. Thus, we propose that Raf is associated with a novel immunophilin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520912

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis.

Authors:  Mei-Hua Zhang; Jae-Seon Lee; Hee-Jung Kim; Dong-Il Jin; Jong-Il Kim; Kong-Joo Lee; Jeong-Sun Seo
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

2.  FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition.

Authors:  G Baughman; G J Wiederrecht; N F Campbell; M M Martin; S Bourgeois
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

3.  Mutations Modulating Raf signaling in Drosophila eye development.

Authors:  B J Dickson; A van der Straten; M Dominguez; E Hafen
Journal:  Genetics       Date:  1996-01       Impact factor: 4.562

Review 4.  Ras-Mediated Activation of the Raf Family Kinases.

Authors:  Elizabeth M Terrell; Deborah K Morrison
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

Review 5.  Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.

Authors:  L Neckers; T W Schulte; E Mimnaugh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function.

Authors:  N Grammatikakis; J H Lin; A Grammatikakis; P N Tsichlis; B H Cochran
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

7.  Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase.

Authors:  Jianxin Sun; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-14       Impact factor: 8.311

8.  Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

Authors:  K Muraoka; K Fujimoto; X Sun; K Yoshioka; K Shimizu; M Yagi; H Bose; I Miyazaki; K Yamamoto
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Hsp90 is required for pheromone signaling in yeast.

Authors:  J F Louvion; T Abbas-Terki; D Picard
Journal:  Mol Biol Cell       Date:  1998-11       Impact factor: 4.138

Review 10.  The therapeutic target Hsp90 and cancer hallmarks.

Authors:  Yoshihiko Miyata; Hitoshi Nakamoto; Len Neckers
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.